Man Group PLC Mannkind Corp Transaction History

Man Group PLC

$54.1 Billion
Q3 2025

A detailed history of Man Group PLC transactions in Mannkind Corp stock. As of the latest transaction made, Man Group PLC holds 98,651 shares of MNKD stock, worth $499,174. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,651

Previous 898,164 89.02%

Holding current value

$499,174

Previous $3.36 Million 84.25%

% of portfolio

0.0%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.42 - $5.74 $2.73 Million - $4.59 Million	-799,513 Reduced 89.02%	98,651 $529,000
Q2 2025 Aug 14, 2025	BUY	$3.71 - $5.04 $993,853 - $1.35 Million	267,885 Added 42.5%	898,164 $3.36 Million
Q1 2025 May 15, 2025	BUY	$4.92 - $6.6 $255,687 - $342,995	51,969 Added 8.99%	630,279 $3.17 Million
Q4 2024 Feb 14, 2025	BUY	$5.93 - $7.44 $1.3 Million - $1.64 Million	219,891 Added 61.35%	578,310 $3.72 Million
Q3 2024 Nov 14, 2024	BUY	$5.01 - $6.7 $591,029 - $790,399	117,970 Added 49.06%	358,419 $2.25 Million

Q2 2024 Aug 14, 2024	BUY	$4.05 - $5.43 $138,753 - $186,031	34,260 Added 16.62%	240,449 $1.26 Million
Q1 2024 May 15, 2024	BUY	$3.25 - $5.27 $214,308 - $347,509	65,941 Added 47.02%	206,189 $934,000
Q4 2023 Feb 14, 2024	BUY	$3.34 - $4.29 $468,428 - $601,663	140,248 New	140,248 $510,000
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $586,505 - $1.04 Million	194,207 Added 296.18%	259,778 $1.37 Million
Q3 2022 Nov 14, 2022	SELL	$2.99 - $4.35 $537,004 - $781,259	-179,600 Reduced 73.25%	65,571 $203,000
Q2 2022 Aug 15, 2022	BUY	$2.67 - $4.77 $504,656 - $901,577	189,010 Added 336.55%	245,171 $934,000
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $147,141 - $249,916	56,161 New	56,161 $207,000

Others Institutions Holding MNKD

# of Institutions

255

Shares Held

165M

Call Options Held

2.76M

Put Options Held

689K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.3B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account